TradeLink Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

TradeLink Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$14K	–	17
2020 Q4	$14K	Hold	20,000	–	–	4.46%	2
2020 Q3	$45K	Hold	20,000	–	–	0.95%	5
2020 Q2	$72K	Sell	20,000 -46,500	-70%	-$168K	0.3%	53
2020 Q1	$252K	Sell	66,500 -500	-0.7%	-$1.65K	7.7%	2
2019 Q4	$202K	Buy	+67,000	New	+$174K	8.05%	3

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

TradeLink Capital's BMY.RT Position: Q1 2021 in Review

TradeLink Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 20,000 shares — an estimated $14K sold.

TradeLink Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $252K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

TradeLink Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
TradeLink Capital sold 20,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $14K.
TradeLink Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
TradeLink Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $252K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on TradeLink Capital's 13F filing for Q1 2021, filed 7 May 2021.